Inhaled COVID-19 Vaccines

Dr. Matthew Miller is Executive Director of Global Nexus and the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University. He also serves as Co-Director of Canadian Pandemic Preparedness Hub (CP2H). Dr. Miller holds a Canada Research Chair in Viral Pandemics. He was recruited to McMaster University in 2014 as an Assistant Professor and has authored over 80 peer-reviewed publications. He has received several major awards, including a CIHR New Investigator Award, the CIHR Bhagirath Singh Early Career Award in Infection and Immunity, and an Early Researcher Award from the Government of Ontario, and a Distinguished Alumni Award for Excellence in Basic Science from Western University.

Dr. Miller’s research program is focused primarily on pandemic prevention, especially the development of broadly-protective vaccines, antibodies, and therapeutics. He sits the scientific advisory board of several major vaccine manufacturers, including Seqirus, Pfizer, and Sanofi. He is a member of the Canadian National Advisory Committee on Immunization (NACI) COVID-19 Working Group and Committee to Advise on Tropical Medicine and Travel (CATMAT), the Federal Variants-of-Concern Leadership Group, the Federal Pandemic Science Coordination and Action Group, and the PHAC Expert Panel on Highly Pathogenic Avian Influenza (HPAI).  He served as Secretary-Treasurer of the Canadian Society for Virology from 2021-2022.

Dr. Matthew Miller is Executive Director of Global Nexus and the Michael G. DeGroote Institute for Infectious Disease Research at McMaster University. He also serves as Co-Director of Canadian Pandemic Preparedness Hub (CP2H). Dr. Miller holds a Canada Research Chair in Viral Pandemics. He was recruited to McMaster University in 2014 as an Assistant Professor and has authored over 80 peer-reviewed publications. He has received several major awards, including a CIHR New Investigator Award, the CIHR Bhagirath Singh Early Career Award in Infection and Immunity, and an Early Researcher Award from the Government of Ontario, and a Distinguished Alumni Award for Excellence in Basic Science from Western University.

Dr. Miller’s research program is focused primarily on pandemic prevention, especially the development of broadly-protective vaccines, antibodies, and therapeutics. He sits the scientific advisory board of several major vaccine manufacturers, including Seqirus, Pfizer, and Sanofi. He is a member of the Canadian National Advisory Committee on Immunization (NACI) COVID-19 Working Group and Committee to Advise on Tropical Medicine and Travel (CATMAT), the Federal Variants-of-Concern Leadership Group, the Federal Pandemic Science Coordination and Action Group, and the PHAC Expert Panel on Highly Pathogenic Avian Influenza (HPAI).  He served as Secretary-Treasurer of the Canadian Society for Virology from 2021-2022.